Adderall vs. Vyvanse: Mechanism, Duration, and Dose Equivalence Explained

Adderall and Vyvanse both raise synaptic dopamine and norepinephrine, but they get there by different routes. Adderall (mixed amphetamine salts) delivers immediate or extended-release amphetamine directly, with effects beginning in 30 to 60 minutes and lasting 4 to 12 hours depending on formulation. Vyvanse (lisdexamfetamine) is an inactive prodrug: enzymes in red blood cells cleave off the amino acid lysine to release active d-amphetamine gradually, producing effects that begin around 1 to 2 hours and last 10 to 14 hours. Neither is inherently "stronger"; per-milligram potency and the conversion ratio between them differ, and Vyvanse carries a lower misuse liability because the active drug cannot be extracted by crushing or snorting.

How Each Drug Reaches the Brain

Amphetamine works by entering the presynaptic neuron through the dopamine transporter and the norepinephrine transporter. Once inside, it does three things: it forces the transporters to run in reverse, pushing dopamine and norepinephrine out into the synapse; it blocks the vesicular monoamine transporter, so newly made neurotransmitter leaks into the cytoplasm instead of being stored; and at higher doses it inhibits monoamine oxidase, slowing breakdown. The net result is a flood of catecholamines in the prefrontal cortex and striatum, the circuits governing attention, working memory, and impulse control.

Adderall is a 3:1 mixture of dextroamphetamine and levoamphetamine salts. The d-isomer drives most of the central stimulant effect; the l-isomer adds peripheral noradrenergic activity and a slightly longer tail of effect. In plain terms: Adderall hands the brain a finished dose of amphetamine all at once or across a controlled release window.

Vyvanse is lisdexamfetamine dimesylate, which is pharmacologically inert until the body acts on it. The prodrug is absorbed intact through the gut, then red blood cells hydrolyze the lysine bond to yield d-amphetamine. Because that cleavage is rate-limited by enzyme availability rather than by the pill dissolving, the rise in blood amphetamine is smoother and slower. Only d-amphetamine is produced, so there is no levoamphetamine component at all.

This mechanistic difference explains most of the downstream contrasts: onset speed, duration, peak sharpness, and the difficulty of extracting a usable stimulant from the capsule.

Onset, Peak, and Duration Side by Side

The comparison below reconciles the timing and dosing differences that drive most real-world prescribing decisions. Figures are approximate population averages; individual metabolism, stomach contents, and CYP2D6 activity shift them.

The equivalence row is the one most often misstated online. Vyvanse 30 mg delivers roughly 8.9 mg of d-amphetamine base, and Adderall's d-amphetamine content per milligram is lower because of its salt mixture and levoamphetamine share. Clinicians therefore use a rough 2:1 to 3:1 conversion (Vyvanse milligrams to Adderall milligrams), not a 1:1 swap. Per the FDA-approved labeling, these conversions are approximations and dose changes should be titrated, not calculated precisely.

In plain terms: 30 mg of Vyvanse is not 30 mg of Adderall. Treating them as interchangeable causes underdosing on one side and overdosing symptoms on the other.

The Timeline of a Single Dose

This is what a typical adult experiences across one treatment day, comparing an immediate-release Adderall dose to a Vyvanse dose. Times are hours after swallowing the capsule.

The clinical takeaway is that Adderall IR produces a sharper on-off curve with a more abrupt afternoon dip, while Vyvanse yields a longer, flatter arc that many people find smoother but that can interfere with sleep if taken after about 9 a.m. The Vyvanse label notes onset within 1 to 2 hours and duration up to 13 hours in some individuals, which is why prescribers often advise early-morning dosing.

Why Vyvanse Has Lower Misuse Potential

The prodrug design is the mechanism behind the regulatory difference. You cannot snort, inject, or smoke lisdexamfetamine to get a fast dopamine spike, because the active d-amphetamine only appears after enzymatic cleavage inside the body, and that cleavage caps how fast blood levels can rise. Crushing a Vyvanse capsule and swallowing the powder produces roughly the same slow curve; snorting the powder yields poor absorption and little rush.

Adderall, by contrast, contains finished amphetamine salts. Crushing an IR tablet and insufflating it or dissolving it for injection delivers a rapid bolus, which is the pharmacokinetic property associated with higher abuse liability. This is why Vyvanse is a Schedule II drug like Adderall but is frequently favored in patients with a history of substance misuse, per prescribing guidance from major psychiatric bodies.

A non-obvious correction: lower misuse liability does not mean lower dependence risk. Daily Vyvanse use still produces tolerance and a withdrawal syndrome (fatigue, low mood, hypersomnia) on abrupt cessation, because the underlying dopamine adaptation is the same. The difference is in the speed of the reward spike, not in whether the brain adapts.

Side Effects and the Cardiovascular Edge Case

Both drugs share the same core adverse-effect profile because they act on the same receptors: appetite suppression, insomnia, dry mouth, elevated heart rate, and increased blood pressure. Pooled trial data put appetite decrease at roughly 20 to 30 percent of patients and insomnia at 10 to 20 percent. Blood pressure rises are typically small, on the order of 2 to 4 mmHg systolic, but the tail matters.

The professional caveat is cardiovascular screening. Stimulants raise resting heart rate by about 3 to 6 beats per minute on average, and the label warns against use in patients with structural heart disease, uncontrolled hypertension, or a history of arrhythmia. A counterintuitive edge case: the longer duration of Vyvanse means a dose taken at 8 a.m. can still be elevating heart rate and blood pressure at 8 p.m., so evening blood pressure readings may look worse on Vyvanse than on Adderall IR even when the average daily exposure is similar.

Per the 2023 American Heart Association guidance on stimulant cardiovascular effects, routine ECG screening is not required for most healthy adults starting these medications, but blood pressure and heart rate should be checked at baseline and after dose titration. Pediatric patients warrant closer monitoring because growth velocity can be affected; growth suppression of about 1 to 2 cm over the first two years has been reported, with partial catch-up afterward.

Red Flags That Require a Call to the Prescriber

Stop and seek medical advice rather than adjusting the dose yourself if any of the following appear. These are not normal side effects and can signal a serious problem.

• Chest pain, palpitations, or fainting at any dose.
• New shortness of breath or unexplained swelling.
• Severe agitation, hallucinations, or paranoia.
• A resting heart rate persistently above 100 beats per minute.
• Blood pressure readings consistently above 140/90 mmHg.
• Signs of serotonin syndrome (fever, tremor, confusion) when combined with other serotonergic drugs.

What to Actually Do When Switching or Choosing

These are concrete actions that turn the pharmacology into a workable plan.

Get the conversion right first. If a clinician switches a patient from Adderall to Vyvanse, expect the Vyvanse milligram number to be roughly 2 to 3 times the Adderall number, then titrate upward over one to two weeks rather than assuming equivalence. The reverse switch requires the same care in the opposite direction.

Time the dose to the schedule. Take Vyvanse no later than about 9 a.m. if sleep matters, and take Adderall IR in a split dose (morning and early afternoon) to smooth the afternoon dip. Extended-release Adderall splits the difference with a two-phase bead release.

Watch the coverage window, not just the peak. Track when focus fades relative to work or school demands; a 6-hour Adderall IR window and a 12-hour Vyvanse window fit different schedules, and mismatch is a common reason for a "failed" trial.

Record blood pressure and heart rate at baseline, at peak, and in the early evening for the first two weeks. This catches the long-duration evening elevation that single morning readings miss.

Keep the diet and sleep basics in view. Because both suppress appetite, plan meals before the dose or after it wears off, and protect sleep timing, since insomnia is the most common reason patients abandon an otherwise effective regimen.

Limits of the Evidence and What Remains Uncertain

Direct head-to-head randomized trials of Adderall versus Vyvanse are sparse. Most comparisons rest on separate trials against placebo plus pharmacokinetic modeling, not on large trials pitting the two against each other. The conversion ratios circulating in clinical practice are derived from amphetamine base content and small crossover studies, and individual response varies widely; two patients at the same milligram dose can show blood levels differing by two- to threefold because of CYP2D6 and other metabolic factors.

The long-term cardiovascular and psychiatric safety data beyond a few years of follow-up are limited, and the growth-suppression findings in children come from observational cohorts rather than long randomized studies. Claims that one drug is categorically "safer" or "more effective" than the other outrun the evidence. Per the FDA labeling for both products, the choice depends on duration needed, misuse history, dosing flexibility, and individual tolerance, and there is no established hierarchy of efficacy between them for ADHD in adults. The honest position is that they are the same active molecule delivered on different time curves, and the right choice is the curve that matches the patient's day, monitored with real numbers rather than assumptions.